This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?The Motley Fool • 09/22/24
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?The Motley Fool • 09/19/24
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.The Motley Fool • 09/18/24
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024Business Wire • 09/16/24
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million SaleInvestors Business Daily • 09/12/24
Summit Hits Record High on Lung Cancer Drug Topping Merck's KeytrudaZacks Investment Research • 09/10/24
Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC SubpopulationSeeking Alpha • 09/09/24
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trialMarket Watch • 09/09/24
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By HalfBenzinga • 09/09/24